

Obr. 3 a 4. Klinický obraz po 4 týdnech terapie bimekizumabem



LITERATURA

1. Reich K, Krüger K, Mössner R, et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. *Br J Dermatol.* 2009;160(5):1040-1047.
2. Pavelka K, Arenberger P, Lukáš M, et al. Biologická léčba zánětlivých autoimunitních onemocnění. Praha: Grada Publishing; 2014. ISBN 978-80-247-5048-4.
3. Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. *J Am Acad Dermatol.* 2005;52(1):1-19.
4. Ibrahim GH, Buch MH, Lawson C, et al. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. *Clin Exp Rheumatol.* 2009;27(3):469-474.
5. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. *Ann Rheum Dis.* 2015;74(6):1045-1050.
6. Villalpando-Vargas FV, Rivera-Valdés JJ, Alvarado-Navarro A et al. Association between IL-17A, IL-17F and IL-17RA gene polymorphisms and susceptibility to psoriasis and psoriatic arthritis: a meta-analysis. *Inflamm Res.* 2021;70(10-12):1201-1210. doi: 10.1007/s00011-021-01514-6. Epub 2021 Oct 27. PMID: 34705056.
7. Ruggiero A, Potestio L, Camela E et al. Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge. *Psoriasis (Auckl).* 2022;12:127-137. doi: 10.2147/PTT.S367744. PMID: 35707807; PMCID: PMC9189155.
8. Tam HKJ, Robinson PC, Nash P. Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms. *Curr Rheumatol Rep.* 2022;24(10):310-320. doi: 10.1007/s11926-022-01084-4. Epub 2022 Jul 21. PMID: 35861937; PMCID: PMC9470681.
9. SPC, Bimzelx 160 mg injekční roztok v předplněném peru/ injekční stříkačce, datum poslední revize textu 5. 6. 2023
10. Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. *Lancet.* 2021;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2. Erratum in: *Lancet.* 2021;397(10275):670. PMID: 33549193.
11. Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. *Lancet.* 2021;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4. Erratum in: *Lancet.* 2021 Mar 27;397(10280):1182. PMID: 33549192.
12. Warren RB, Blauvelt A, Bagel J et al. Bimekizumab versus Adalimumab in Plaque Psoriasis. *N Engl J Med.* 2021;385(2):130-141. doi: 10.1056/NEJMoa2102388. Epub 2021 Apr 23. PMID: 33891379.
13. Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus Secukinumab in Plaque Psoriasis. *N Engl J Med.* 2021;385(2):142-152. doi: 10.1056/NEJMoa2102383. Epub 2021 Apr 23. PMID: 33891380.
14. Gordon KB, Langley RG, Warren RB, et al. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. *JAMA Dermatol.* 2022;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185. PMID: 35544084; PMCID: PMC9096693.
15. McInnes IB, Ashina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naïve to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). *Lancet.* 2023;401:25-37.
16. Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor- α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). *Lancet.* 2023;401:38-48.